<DOC>
	<DOCNO>NCT01757626</DOCNO>
	<brief_summary>The purpose study find antibody call Humanized 3F8 ( Hu3F8 ) combine granulocyte- macrophage colony stimulate factor ( GM-CSF ) safe treat neuroblastoma .</brief_summary>
	<brief_title>Combination Therapy Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor ( GM-CSF ) Patients With Relapsed/Refractory High-Risk Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosis NB define ) histopathology ( confirm MSKCC Department Pathology ) , b ) BM metastases MIBGavid lesion ( ) plus high urine catecholamine level . Patients must highrisk NB ( include MYCNamplified stage 2/3/4/4S age MYCNnonamplified stage 4 patient great 18 month age ) AND : Phase I : Patients must refractory relapsed NB , resistant standard therapy* . *For NB , standard therapy include intensive induction chemotherapy , follow variety consolidation salvage therapy , depend response . Phase II : Patients must primary secondary refractory disease BM , define morphologic evidence NB BM and/or abnormal 123IMIBG uptake osteomedullary site , OR patient ≥2nd CR/VGPR Patients must older 1 year age . Prior treatment murine humanize 3F8 allow . Patients prior m3F8 , hu3F8 , ch14.18 hu14.18 treatment must HAHA antibody titer ≤1300 Elisa units/ml . Human antimouse antibody positivity allow . White blood cell count ≥1000/ul ( phase I ) Absolute neutrophil count ≥500/ul ( phase I ) Absolute lymphocyte count ≥500/ul ( phase I ) Platelet count ≥25,000/ul ( phase I ) No chemotherapy immunotherapy minimum three week prior start hu3F8 Women childbearing potential must willing practice effective method birth control treatment Signed informed consent indicate awareness investigational nature program . Existing major organ dysfunction &gt; grade 2 , exception hearing loss hematologic toxicity ( defined suppression subtypes WBCs , RBCs , platelet ) . Active lifethreatening infection . Pregnant woman woman breastfeed . Inability comply protocol requirement , include PK study genetic study ( phase I ) History allergy mouse proteins . Human antihu3F8 antibody ( HAHA ) titer &gt; 1300 Elisa units/ml . History allergy GMCSF</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bone Marrow</keyword>
	<keyword>Hu3F8</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>12-230</keyword>
</DOC>